Research progress on the mechanism of organ-specific lung metastasis in pancreatic cancer

doi:10.19401/j.cnki.1007-3639.2023.11.008

Abstract

Abstract:

Pancreatic cancer is a highly malignant tumor of the digestive system. Due to the non-specific clinical symptoms in the early stage, its early diagnosis is very difficult. Almost half of the patients with pancreatic cancer have already developed distant metastases at the time of initial diagnosis. In recent years, organ-specific metastasis of pancreatic cancer has received extensive attention. Patients with lung metastasis of pancreatic cancer have shown significant survival benefits. Compared with other metastatic sites, lung metastasis of pancreatic cancer also shows significant differences in gene expression, tumor microenvironment, tumor stem cells and other aspects. This review summarized the research progress on the mechanism of organ-specific lung metastasis in pancreatic cancer.

Key words: Pancreatic cancer, Organ-specific metastasis, Lung metastasis

CLC Number:

R735.9

YUE Ming, WANG Liwei, CUI Jiujie. Research progress on the mechanism of organ-specific lung metastasis in pancreatic cancer[J]. China Oncology, 2023, 33(11): 1026-1031.

References 38

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.v71.3
[2]	CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791.
[3]	MIZRAHI J D, SURANA R, VALLE J W, et al. Pancreatic cancer[J]. Lancet, 2020, 395(10242): 2008-2020. doi: S0140-6736(20)30974-0 pmid: 32593337
[4]	SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. doi: 10.3322/caac.v72.1
[5]	SPRINGFELD C, JAGER D, BUCHLER M W, et al. Chemotherapy for pancreatic cancer[J]. Presse Med, 2019, 48(3): E159-E174. doi: 10.1016/j.lpm.2019.02.025
[6]	KRUGER S, HAAS M, BURGER P J, et al. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer[J]. Pancreatology, 2016, 16(4): 593-598. doi: 10.1016/j.pan.2016.03.016 pmid: 27067420
[7]	KAMISAWA T, ISAWA T, KOIKE M, et al. Hematogenous metastases of pancreatic ductal carcinoma[J]. Pancreas, 1995, 11(4): 345-349. doi: 10.1097/00006676-199511000-00005
[8]	YACHIDA S, IACOBUZIO-DONAHUE C A. The pathology and genetics of metastatic pancreatic cancer[J]. Arch Pathol Lab Med, 2009, 133(3): 413-422. doi: 10.1043/1543-2165-133.3.413 pmid: 19260747
[9]	HO W J, ERBE R, DANILOVA L, et al. Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways[J]. Genome Biol, 2021, 22(1): 154. doi: 10.1186/s13059-021-02363-6 pmid: 33985562
[10]	OETTLE H, NEUHAUS P, HOCHHAUS A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial[J]. JAMA, 2013, 310(14): 1473-1481. doi: 10.1001/jama.2013.279201 pmid: 24104372
[11]	SINN M, BAHRA M, LIERSCH T, et al. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase Ⅲ trial[J]. J Clin Oncol, 2017, 35(29): 3330-3337. doi: 10.1200/JCO.2017.72.6463
[12]	SINN M, LIERSCH T, RIESS H, et al. CONKO-006: a randomised double-blinded phase Ⅱb-study of additive therapy with gemcitabine+sorafenib/placebo in patients with R1 resection of pancreatic cancer-final results[J]. Eur J Cancer, 2020, 138: 172-181. doi: 10.1016/j.ejca.2020.06.032
[13]	KURRECK A, WECKWERTH J, MODEST D P, et al. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma-a pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials[J]. Eur J Cancer, 2021, 150: 250-259. doi: 10.1016/j.ejca.2021.03.036
[14]	NEOPTOLEMOS J P, PALMER D H, GHANEH P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet, 2017, 389(10073): 1011-1024. doi: S0140-6736(16)32409-6 pmid: 28129987
[15]	KIM S, ITCHINS M, ARENA J, et al. Patterns and determinants of recurrence for pancreatic ductal adenocarcinoma after resection[J]. J Pancreas. 2017, 18(6): 458-464.
[16]	LIU K H, HUNG C Y, HSUEH S W, et al. Lung metastases in patients with stage Ⅳ pancreatic cancer: prevalence, risk factors, and survival impact[J]. J Clin Med, 2019, 8(9): E1402.
[17]	GUERRA F, BARUCCA V, COLETTA D. Metastases or primary recurrence to the lung is related to improved survival of pancreatic cancer as compared to other sites of dissemination. Results of a systematic review with meta-analysis[J]. Eur J Surg Oncol, 2020, 46(10 Pt A): 1789-1794. doi: S0748-7983(20)30533-3 pmid: 32753117
[18]	KRUGER S F, LOHNEIS A, ABENDROTH A, et al. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study[J]. ESMO Open, 2022, 7(1): 100388. doi: 10.1016/j.esmoop.2022.100388
[19]	BUSCAIL E, CHAUVET A, QUINCY P, et al. CD63-GPC1-positive exosomes coupled with CA19-9 offer good diagnostic potential for resectable pancreatic ductal adenocarcinoma[J]. Transl Oncol, 2019, 12(11): 1395-1403. doi: S1936-5233(19)30180-9 pmid: 31400579
[20]	KÜNZLI B M, BERBERAT P O, ZHU Z W W, et al. Influences of the lysosomal associated membrane proteins (Lamp-1, Lamp-2) and Mac-2 binding protein (Mac-2-BP) on the prognosis of pancreatic carcinoma[J]. Cancer, 2002, 94(1): 228-239. pmid: 11815981
[21]	LI M, WU X D, LIU N, et al. Silencing of ATF2 inhibits growth of pancreatic cancer cells and enhances sensitivity to chemotherapy[J]. Cell Biol Int, 2017, 41(6): 599-610. doi: 10.1002/cbin.10760 pmid: 28318081
[22]	JEON Y H, HA M, KIM S W, et al. Evaluation of the prognostic significances of γ-secretase genes in pancreatic cancer[J]. Oncol Lett, 2019, 17(5): 4614-4620. doi: 10.3892/ol.2019.10113 pmid: 30944650
[23]	FERGUSON M D, DONG L, WAN J, et al. Molecular alterations associated with DNA repair in pancreatic adenocarcinoma are associated with sites of recurrence[J]. J Gastrointest Cancer, 2019, 50(2): 285-291. doi: 10.1007/s12029-018-0073-8 pmid: 29427136
[24]	FORMICA V, DOLDO E, ANTONETTI F R, et al. Biological and predictive role of ERCC1 polymorphisms in cancer[J]. Crit Rev Oncol Hematol, 2017, 111: 133-143. doi: S1040-8428(16)30262-1 pmid: 28259288
[25]	ULKER M, DUMAN B B, SAHIN B, et al. ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine[J]. Contemp Oncol (Pozn), 2015, 19(3): 207-213.
[26]	LIU Y, CAO X. Characteristics and significance of the pre-metastatic niche[J]. Cancer Cell, 2016, 30(5): 668-681. doi: S1535-6108(16)30446-9 pmid: 27846389
[27]	ARMACKI M, POLASCHEK S, WALDENMAIER M, et al. Protein kinase D1, reduced in human pancreatic tumors, increases secretion of small extracellular vesicles from cancer cells that promote metastasis to lung in mice[J]. Gastroenterology, 2020, 159(3): 1019-1035.e22. doi: S0016-5085(20)34705-3 pmid: 32446697
[28]	GRÜNWALD B, HARANT V, SCHATEN S, et al. Pancreatic premalignant lesions secrete tissue inhibitor of metalloproteinases-1, which activates hepatic stellate cells via CD63 signaling to create a premetastatic niche in the liver[J]. Gastroenterology, 2016, 151(5): 1011-1024.e7. doi: 10.1053/j.gastro.2016.07.043
[29]	WANG Y, LIANG Y Y, XU H Y, et al. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response[J]. Cell Discov, 2021, 7(1): 36. doi: 10.1038/s41421-021-00271-4 pmid: 34035226
[30]	XIAO Q, ZHOU D E, RUCKI A A, et al. Cancer-associated fibroblasts in pancreatic cancer are reprogrammed by tumor-induced alterations in genomic DNA methylation[J]. Cancer Res, 2016, 76(18): 5395-5404. doi: 10.1158/0008-5472.CAN-15-3264 pmid: 27496707
[31]	PAN X Y, ZHOU J J, XIAO Q, et al. Cancer-associated fibroblast heterogeneity is associated with organ-specific metastasis in pancreatic ductal adenocarcinoma[J]. J Hematol Oncol, 2021, 14(1): 184. doi: 10.1186/s13045-021-01203-1
[32]	SASAKI T, NISHIWADA S, NAKAGAWA K, et al. Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer[J]. Int J Clin Oncol, 2022, 27(5): 948-957. doi: 10.1007/s10147-022-02131-x pmid: 35142963
[33]	HERMANN P C, HUBER S L, HERRLER T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer[J]. Cell Stem Cell, 2007, 1(3): 313-323. doi: 10.1016/j.stem.2007.06.002 pmid: 18371365
[34]	LI C W, HEIDT D G, DALERBA P, et al. Identification of pancreatic cancer stem cells[J]. Cancer Res, 2007, 67(3): 1030-1037. doi: 10.1158/0008-5472.CAN-06-2030 pmid: 17283135
[35]	NIMMAKAYALA R K, LEON F, RACHAGANI S, et al. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma[J]. Oncogene, 2021, 40(1): 215-231. doi: 10.1038/s41388-020-01518-2 pmid: 33110235
[36]	LU W, KANG Y B. Epithelial-mesenchymal plasticity in cancer progression and metastasis[J]. Dev Cell, 2019, 49(3): 361-374. doi: S1534-5807(19)30280-1 pmid: 31063755
[37]	REYNOLDS A B, ROCZNIAK-FERGUSON A. Emerging roles for p120-catenin in cell adhesion and cancer[J]. Oncogene, 2004, 23(48): 7947-7956. doi: 10.1038/sj.onc.1208161 pmid: 15489912
[38]	REICHERT M, BAKIR B, MOREIRA L, et al. Regulation of epithelial plasticity determines metastatic organotropism in pancreatic cancer[J]. Dev Cell, 2018, 45(6): 696-711.e8. doi: S1534-5807(18)30418-0 pmid: 29920275